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Summary Following EMS mutagenesis, three estramustine (EM) resistant DU 145 human prostatic car-
cinoma cell lines were clonally selected by exposure to incrementally increasing concentrations of the drug.
Although only low levels of resistance (approximately 3-fold) were attainable, this resistance was stable in the
absence ofcontinuous drug exposure. These EM-resistant clones (EMR 4,9,12) did not exhibit cross resistance
to vinblastine, taxol, or adriamycin, and had collateral sensitivity to cytochalasin B. None of the lines had
elevated expression of P-glycoprotein mRNA or glutathione S-transferase activity, suggesting a phenotype
distinct from the classic multi-drug resistance phenotype. This conclusion was supported further by the
observation that two MDR cell lines (FLC mouse erythroleukaemic and SKOV3 human ovarian carcinoma
cells) showed sensitivity to EM. Fluorescent activated cell sorting analysis of the effects of EM on cell cycle
traverse revealed that at EM concentrations up to 20 M an increasing percentage of wild type cells were
blocked in G2/M; no such effect occurred in EMR lines. Differential interference contrast microscopy was
employed to study EM's effect on mitosis. EMR lines were able to form functional, albeit smaller, spindles at
EM concentrations that resulted in chromosomal disorganisation and inhibition of mitotic progression in wild
type cells. EMR lines were able to progress through mitosis and cytokinesis at the same rate as untreated cells.
Tritiated EM was used to evaluate potential drug uptake/efflux mutations in EMR clones. EMR 4 and 9
incorporate less EM than wild type cells; however, they have significantly decreased cellular volumes. The
initial efflux rate constants for EMR clones were greater than for wild type cells. Within 5 min >70% of the
drug was lost from resistant cells compared to a 50% loss by the wild type. Although the specific mechanisms
of resistance have yet to be defined, the lack of collateral resistance to other MDR/anti-microtubule agents
could serve as the basis for the clinical use of EM in combination chemotherapy.
Estramustine (EM) is a chemotherapeutic agent used in the
treatment of hormone-refractory, advanced prostate carcin-
oma (Jonsson et al., 1977; Kuss et al., 1980). As illustrated in
Figure 1, EM is an oestradiol linked to nor-nitrogen mustard
through a carbamate-ester bond, which is largely responsible
for the unusual pharmacologic properties of the drug. The
stability of this bond accounts for the long clinical half-life of
the parent molecule (Gunnarsson et al., 1981; Gunnarsson et
al., 1984). In addition, in vitro studies revealed that EM acts
independently of its constituent alkylating and estrogen
moieties (Tew, 1983; Tew et al., 1983). Specifically, EM binds
noncovalently to microtubule associated proteins (MAPs)
producing microtubule disassembly, stathmokinesis, and
eventual cell death (Hartley-Asp, 1984; Stearns & Tew, 1985;
Stearns & Tew, 1988; Kanje et al., 1985). EM also binds a
cytoplasmic protein which has been demonstrated in high
concentrations in the ventral prostate of both rat and man
(Bjork et al., 1982; Forsgren et al., 1979a). This protein,
subsequently named estramustine binding protein (EMBP)
serves to localize EM in prostate tissue and binds the drug
with a high affinity and high capacity (Forsgren & Bjork,
1984; Forsgren et al., 1979b).
One of the major obstacles to cancer chemotherapy is that
tumours develop resistance to drugs used for treatment; there-
fore, understanding the mechanisms by which this resistance
is developed is important for improved clinical applications.
Towards this goal, we studied the potential mechanisms by
which human prostate carcinoma cell lines (DU 145) become
resistant to EM. Estramustine, in common with some MDR
drugs, exhibits anti-microtubule effects (Bech-Hansen et al.,
1976; Beck, 1983); therefore, we compared EM-resistance
properties with the multidrug resistance phenotype, as well as
other anti-microtubule agents. Multidrug resistance is charac-
terised by cross-resistance to structurally and functionally
unrelated drugs, overexpression of plasma membrane P-
glycoprotein, and increased levels of the detoxification en-
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Figure 1 Chemical structure of estramustine. Estradiol is con-
nected to nor-nitrogen mustard through a carbamate-ester lin-
kage.
zyme glutathione S-transferase pi (Ling & Thompson, 1974;
Ling, 1975; Kartner et al., 1983; Batist et al., 1986). Because
microtubules play a major role during mitosis and EM
exhibits anti-microtubule properties, we examined the drug's
effect on the cell cycle of both sensitive and resistant lines.
Other types of drug resistance include altered drug transport
mechanisms. Using 3H-EM, we investigated the possibility
that differential drug uptake and/or efflux characteristics were
responsible for the development of EM resistance.
The goal of our study was three-fold: (1) to produce
EM-resistant DU 145 human prostate carcinoma cells lines,
(2) compare EM resistance to that of the MDR phenotype,
(3) study the effect of EM on mitosis in both wild type and
resistant lines.
Materials and methods
Cell culture
Human prostatic carcinoma cell lines (DU 145) were cultured
in complete media (Dulbecco's Modified Eagle Media supp-
lemented with 4mM L-glutamine, 1 mM sodium pyruvate,
1% penicillin/streptomycin, and 10% foetal bovine serum
(FBS)). Murine erythroleukemic cells sensitive (FLC) and
resistant (ARNI, 2 and 3) to adriamycin (cells kindly pro-
vided by Haim Tapiero) were grown in RPMI-1640 media
supplemented with 10% FBS and 1% penicillin/streptomy-
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cin. Human ovarian carcinoma cells sensitive (SKOV3) and
resistant (SKVLB) to vinblastine (cells kindly provided by
Victor Ling) were grown in a-MEM supplemented with
15% FBS. SKVLB cells were grown in medium containing
1 fg ml-' vinblastine. All cell lines were incubated at 37°C in
a humidified, 5% CO2 atmosphere.
Establishment ofestramustine resistant lines
DU 145 cells were mutagenised with 300jgml-' ethylme-
thane sulfonate for 36 h, refed with fresh media, and plated
onto T-80 dishes in 10JLM EM. Surviving colonies were
harvested and passaged at a 1:5 ratio in low (2.5,sM) EM
concentrations and maintained in constant exposure to drug.
Resistance was achieved through sequential passages in in-
creasing EM concentrations.
Collateral resistance/sensitivity assays
Patterns of collateral resistance of wild type and EMR lines
to anti-microtubule/MDR agents (adriamycin, cytochalasin
B, taxol, vinblastine) were determined using colony forming
assays. Cell monolayers were trypsinised from flasks, counted
and plated directly into media containing drug at a density of
500 cells/25 cm2 tissue culture flask. Cells were maintained in
constant exposure to drug at 37°C in 5% CO2 for 10-12
days. Surviving colonies (>32 cells) were fixed with metha-
nol/acetic acid (90:10), stained with 1% crystal violet, and
counted using a Biotran III automatic totalizer (New Bruns-
wick Scientific, Edison, NJ). Percentage of surviving colonies
were calculated by comparison to control flasks and plotted
as a function of drug concentration. IC50 values were cal-
culated from linear regression analysis of plotted values.
Characterisation assays
The stability of resistance of the EMR clones to EM was
determined by survival assays. Cells were cultured in the
absence of drug for 12 weeks (approximately 75 population
doublings) and colony forming assays using EM concentra-
tions of 0-20 jAM were performed.
To calculate the population doubling times of wild type
and EMR clones, cells were plated onto 6 well tissue culture
plates at 10% confluency (7-8 x 103 cellscm-2) and cell
counts were taken at the same time on five consecutive days.
Individual wells were washed 1 x with phosphate buffered
saline, trypsinised (0.25% trypsin with .02% EDTA) and
counted on a Coulter Counter (Model ZM, Coulter Elec-
tronics, Inc., Hialeah, FL). Triplicate wells were counted for
each time point and the experiment was repeated three times.
Glutathione (GSH) levels and GST activity were determined
through methods previously published (Griffith, 1980; Habig
et al., 1974).
Northern blot analysis ofRNAfrom wild type andresistant
lines
Total cellular RNA was isolated by an acid-phenol-chloro-
form extraction (Chomczynski & Sacchi, 1987), and elec-
trophoresed in 1% agarose - 6% formaldehyde gels. Twenty
tig of total RNA was loaded per lane. RNA gels were
visualised by ethidium bromide staining to ensure that equiv-
alent amounts of RNA were being analysed. Separated RNA
species were transferred to Magna NT membrane filters
(Micron Separations, Inc., Westboro, MA) by capillary elu-
tion in 10 x SSC and hybridised with 32P-labelled pCHPI
insert (a 600 bp P-glycoprotein cDNA sequence; Riordan
et al., 1985) nick-translated to a specific activity of
-4x 108d.p.m.jig-'. Filters were washed twice for 30min
each in 2 x SSC, 0.5% SDS, and 0.1% sodium pyrophos-
phate at 65TC and twice in 0.2 x SSC, 0.5% SDS, and 0.1%
sodium pyrophosphate at 55°C. Autoradiography was per-
formed at -70C for 1 week.
FACs
Fluorescent activated cell sorting was employed to study
EM's effect on the cell cycle. Wild type and EMR clones
were exposed to EM (0, 2.5, 10, 20JLM) for 36 h and
prepared for FACs according to the procedure ofVindelov et
al. (1983). Cellular DNA content was analysed on a FAC-
Scan (Becton Dickinson Immunocytometry Systems, San
Jose, CA). Data are reported as the percentage of a given
population in a specific phase of the cell cycle (GI, S, or
G2/M).
Microscopy
Living cells were prepared for differential interference con-
trast (DIC) microscopy as follows. Cells were plated onto
sterile glass coverslips 3 days prior to use in order to obtain
mitotic cells which were relatively flat and thus, optimal for
DIC microscopy. The coverslips were placed on slides and
buffered with 25 mM HEPES and the slide was maintained at
37°C via an air curtain (Laboratory Products, Inc., Boston,
MA). EM-resistant lines were maintained in drug prior to,
and throughout the course of observation. Video-enhanced
DIC microscopy was performed utilising a DAGE New-
vicon (DAGE-MTI, Inc., Michigan City, IN) video camera,
Hughes Aircraft model 794 image processor (Hughes Aircraft
Co., Los Angeles, CA), Panasonic 794 time/date generator
(Panasonic, Inc., Secaucas, NJ) and Sony 5800 3/4 (Sony
Corp., Long Island City, NY) video recorder.
Analysis ofcellular uptake andrelease of3H-EM
3H-estramustine (2,4,4,7-3H) was provided by Pharmacia Leo
Therapeutics AB (Helsingborg, Sweden). Radiochemical pur-
ity was determined by high performance liquid chromatog-
raphy to be >98%.
Uptake of 3H-EM was determined by incubating cells for
time periods from 0-24 h at 37°C with 1 iLCi ml-' of labelled
EM in media containing 2.5tLM cold drug. At each time
point, cells were washed with cold PBS, trypsinised and an
aliquot removed for cell number determination. Cells were
centrifuged through silicon/mineral oil (4:1) at 13,000g for
3 min, media and oils were carefully aspirated and cell pellets
were resuspended in a hypertonic lysis buffer. Cells were
transferred to scintillation vials with 5.0 ml Ecoscint A scin-
tillation fluid and radioactivity was determined with a Beck-
man LS 9800 liquid scintillation counter.
Drug efflux was determined following an initial 2 h incuba-
tion of cells with 3H-EM in the conditions described above.
Drug-containing media was aspirated from cells, which were
then washed and refed in drug-free media. At time-points
from 0 min-4 h post drug-incubation, cells were prepared as
described above. All experiments were performed in triplicate
and repeated at least twice.
Rate constants for drug efflux were calculated using non-
linear regression analysis.
Cell volume calculation
Cell volumes were determined using an electronic particle
counter equipped with a size-distribution analyser (Coulter
Electronics, Inc., Hialeah, FL). Accumulated data was dis-
played graphically and digitally and plotted on an XY
recorder. Ragweed pollen standard was used to calculate the
calibration constant (K). Cell volumes (V) were calculated
from the following equation:
V(um3) = (K x (1/APC) x (1/AMP) x T
where APC = aperture current, AMP = amplification and T
is the modal threshold value determined graphically.ESTRAMUSTINE RESISTANCE 269
Results
Establishment and characterisation ofestramustine resistant
prostate carcinoma cell lines
Colony forming assays performed under conditions of con-
tinuous exposure to EM determined that wild type cells
exhibited an approximate ICgo value of 10gAM. EM-resis
tant clones (EMR) were established following mutagenesis,
through an initial selection of clones surviving 1O JM EM,
followed by continued exposure to increasing drug concentra-
tions. Three EMR clones exhibiting an approximate three
fold increased resistance to EM compared to the wild type
cell line were selected (Figure 2).
The population doubling times for the EMR lines
(24-25 ± 2 h) were not significantly different from that ofthe
wild type (26 ± 1 h). In addition, doubling times for EMR
clones grown in the presence of 12 JM EM were not
significantly different than those for clones grown in the
absence of drug (Table I).
The stability of resistance of the EMR clones was deter-
mined by colony forming assays after removal of cells from
drug for 12 weeks (approximately 75 population doublings).
All clones tested maintained a significantly increased level of
EM resistance compared to the wild type cells (Table II). In
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Figure 2 Estramustine's effect on cell survival of wild type and
EMR cell lines. Data are presented as percent cell survival as a
function of estramustine concentration. Values represent results
of three experiments performed in triplicate ± standard error of
the mean. EMR clones exhibit a three fold increased level of
resistance compared to wild type. (0) wild type; (A) EMR 4;
(0) EMR 9; (O) EMR 12.
Table I Calculated doubling times: wild type and EMR cell lines
Doubling time (H)
Cell type Drug absence Presence of 12 lam EM
Wild type 26.3 1.0 *
EMR 4 25.5 2.9 25.3 ± 2.4
EMR 9 23.5± 3.3 24.0 ± 0.9
EMR 12 21.8 _ 1.8 23.7 ± 2.9
Cells were plated at a 10% initial seeding density in either 12 AM EM
or in the absence ofdrug. Cell counts were taken at the same time for
four consecutive days. Doubling time values calculated represent an
n = 6 ± standard error ofthe mean. *Wild type cells were not plated in
12gM EM, as this would result in 100% cell kill.
Table II Stability of estramustine resistant DU 145 cell lines
Cell line IC50fAM* ICZ JAM Fold resistance
Wild type 2.8 (1) 7.2 (1)
EMR 4 (+ drug) 14.6 (5.2) 24.4 (3.4) 4.3
EMR 4 (- drug) 11.7 (4.2) 21.0 (2.9) 3.6
EMR 12 (+ drug) 10.5 (3.8) 17.9 (2.5) 3.2
EMR 12 (+drug) 9.2 (3.3) 17.5 (2.4) 2.9
*IC",/o values were calculated by linear regression analysis ofresults
ofcolony formini assays carried out with continual exposure to drug.
Values represent an n = 3. Values in parenthesis represent fold
resistancecompared todrug sensitiveparentals. Resistantcell lines were
grown in the absence ofdrug for 12 weeks prior to experiment. Other
resistant clones wvhich have not been reported in this manuscript also
demonstrate stability to EM.
addition, calculated EM IC50 and IC90 values for EMR clones
removed from drug were compared to those of cells main-
tained in the continual presence of drug. Results of cell
growth assays in the presence of variable EM concentrations
revealed that the EMR clones removed from drug were able
to maintain the same degree of resistance to EM as those
continually exposed to drug.
Estramustine is distinctfrom the multi-drug resistance
phenotype
Cross resistance and biological characterisation assays were
performed in order to determine if EM resistance was distinct
from the MDR phenotype. Survival assays examined the
patterns of cross resistance of wild type and EMR cell lines
to anti-mitotic/MDR agents. Results from survival assays
with vinblastine, adriamycin, taxol, and cytochalasin B are
shown in Table III. None of the EMR clones exhibited an
increased resistance (compared to wild type) to any of the
drugs examined. However, all EMR clones had an approx-
imate three fold increased sensitivity to cytochalasin B. In
addition, EMR 12 was approximately twice as sensitive to
adriamycin as the wild type line.
Additional support of the hypothesis that EM resistance
was distinct from MDR phenotype came from experiments
with two carcinoma cell lines known to be part of the MDR
phenotype. Friend erythroleukaemic cells (FLC) made resis-
tant to adriamycin (ARN; Tapiero et al., 1984) and human
ovarian carcinoma cells (SKOV3) made resistant to vinblas-
tine (SKVLB; Bradley et al., 1989), both demonstrate cross
resistance to other anthracylines and vinca alkaloids. The
sensitivity of these cells to EM was tested and ICs values for
wild type and resistant clones are given in Table IV. None of
the resistant clones demonstrated an increased resistance to
EM. However, ARN cell lines did exhibit an increased sen-
sitivity to EM.
One of the primary alterations in MDR cells is an
increased expression of the MDR1 gene product, plasma
membrane P-glycoprotein. Therefore, using Northern blot
analysis, EMR clones were tested for increased message levels
of P-glycoprotein. As seen in Figure 3, EMR clones did not
Table III Cross resistance of estramustine-resistant DU 145 cells
toward anti-mitotic/MDR drugs
IC50 Values (relative degree ofresistance)
Wild type EMR 4 EMR 9 EMR 12
Estramustine 2.8 (1) 9.2 (3.3) 8.1 (2.9) 8.8 (3.2)
(jtg/ml)
Adriamycin 6.9 (1) 8.7 (1.3) 6.1 (0.9) 3.0 (0.4)
(ng/ml)
Cytochalasin B 14.0 (1) 5.0 (0.4) 5.5 (0.4) 4.8 (0.3)
(Ag/ml)
Taxol 2.5 (1) 1.7 (0.7) 2.7 (1.1) 3.1 (1.2)
(ng/ml)
Vinblastine 1.8 (1) 1.6 (0.9) 1.8 (1.0) 1.6 (0.9)
(ng/ml)
Colony forming assays were performed in continuous exposure to
drug as described in Methods. IC50 values were calculated by linear
regression analysis ofresults ofat least three experiments performed in
triplicate. EMR clones do not exhibit increased resistance to any ofthe
drugs tested; however, an increased sensitivity to cytochalasin B is
noted.
Table IV Estramustine ID50 values for MDR cell lines
Cell line Resistant to: (fold resistance) EMID50 (AM)
SKOV3 Wild Type 6.4
'SKVLB Vinblastine (100 x) 6.2
FLC Wild type 4.3 (1)
2ARN 1 Adriamycin (2.5 x) 2.7 (0.6)
ARN 2 (13 x) 2.9 (0.7)
ARN 3 (> 100 x) 1.4 (0.3)
'"2SKVLB and ARN cell lines weremade resistant to vinblastine and
adriamycin, respectively, but demonstrate cross resistance to other
anthracyclines andvincaalkaloids(seerefs.Tapieroetal., 1984;Bradley
et al., 1989). Values in parentheses represent fold increase in resistance
compared to wild type cells.
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Figure 3 Northern blot hybridisation with the P-glycoprotein
cDNA probe pCHPI. Total RNA was size-fractionated on
agarose gels, transferred to nylon membrane filters and hybri-
dised with 32P-labelled pCHPI as described in Methods. The
ethidium-bromide stained RNA gel (right panel) ensures that
equivalent amounts of RNA were analysed. Lanes: (1) human
ovarian carcinoma cell line (2780) - negative control; (2) and (3)
colon carcinoma cell line HCT15 (sensitive) and HCT15 CP16
(cisplatinum-resistant) both positive. controls for MDR 1 RNA
expression; (4) wild type; (5), (6), and (7), EMR 4, 9 and 12
respectively. Neither the wild type nor EMR cell lines overexpress
MDR-1 RNA.
overexpress P-glycoprotein mRNA. Western blot analysis
confirmed these results and showed EMR clones exhibited
undetectable levels of P-glycoprotein (data not shown). Be-
cause thiols may be an important factor in both MDR and
other forms of drug resistance, and EM may be a potential
substrate for GSTs (Tew et al., 1986), both GSH levels and
total GST activity in drug sensitive and EMR clones were
measured. No significant changes in GST or GSH levels were
found for EMR cell lines (data not shown).
Estramustine's effect on the cell cycle
Estramustine binds to microtubule associated proteins
(MAPs), causing microtubule disassembly and a metaphase
block. Using FACs, the effect of EM (36 h exposure) on the
cell cycle of wild type and EMR clones was compared. As
expected for wild type cells, increased concentrations of EM
resulted in an increased build up of cells at the G2/M phase
of the cell cycle. Approximately 11I% of DU 145 cells were in
G2/M when no drug was present. With increasing EM con-
centrations of2.5, 10, and 20 JAm the percent of cells in G2/M
increased to 20%, 38.2%, and 74.3%, respectively. In con-
trast, the percent of EMR cells in G2/M did not change
significantly with exposure to increased EM concentrations.
Figure 4 illustrate the percent of wild type and EMR clones
in each phase of the cell cycle as a function of EM concen-
tration.
Estramustine's effect on the mnitotic spindle
Differential interference contrast (DIG) microscopy was em-
ployed to study the effect of EM on mitosis in the EMR cell
lines. Drug-sensitive, wild type mitotic cells treated with EM
concentrations as low as 2.5 JAm lost microtubule organisa-
tion resulting in chromosomal disorganisation and inhibition
of mitotic progression. Sensitive cells were unable to form
functional spindles when treated with EM concentrations of
10-15 JAm (data not shown). In contrast, EMR clones treated
with 15 JAm EM were capable of forming functional, albeit
smaller spindles, and progressed through anaphase and cyto-
kinesis at the same rate as untreated cells (Figure 5).
Uptake/efflux analysis of3H1-EM in EMR and wild type
cells
Tritiated EM was used to investigate potential differential
uptake/efflux characteristics of the sensitive and resistant cell
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Figure 4 Fluorescent activated flow cytometry analysis of estra-
mustine's effect on the cell cycle of wild type a and EMR b, c cell
lines: Data are presented as the percentage of cells in a certain
cycle phase as a function of estramustine concentration. With
increasing EM concentrations, there is a proportional increase in
the percent of wild type cells blocked in G2/M. In contrast, the
percent of EMR cells in G2/M does not change with increasing
EM concentrations. (0) GI; (0) S; (A) G2/M.
lines. Initial uptake of 'H-EM by both resistant and sensitive
cells was a rapid process. Within 5 min cells contained
>50% of the total drug incorporated and by h maximum
uptake was reached (Figure 6a). The maximum EM content
of the wild type cells was double that of EMR 4 and 9;
however, the modal cell volumes of the EMR clones was
only 45-50% of the wild type line. Both resistant and sen-
sitive cells lines followed a biphasic drug-effiux profile; how-
ever, a marked difference in their rate constants was observed
(Figure 6b). EMR 4, 9 and 12 had much greater initial effiux
rate constants compared to the wild type. Within 5 mmn, the
EMR clones lost 70-75% of the drug compared to a 50%
loss in the wild type line. The secondary phase of effiux of all
cell lines was much slower with half lives ranging from
200-330 min.
Discussion
The unique interactions of EM with MAPs serve as a basis
for comparison with other anti-microtubule agents with re-
spect to drug resistance. In the studies carried out to this
time, most cell lines resistant to microtubule active drugs fall
into two categories: (1) efflux mutants (i.e., cells expressing
the multidrug-resistant phenotype) (Ling, 1974; for review see
Schibler and Cabral, 1985), (2) mutants exhibiting tubulin
subunit alterations (Cabral & Barlow, 1989). The majority of
the studies performed have been with Chinese hamster
ovary cells, which fall into the MDR category. In order to
compare EM with other anti-microtubule/MDR agents, we
produced EM-resistant DU 145 clones (EMR). Levels of
attainable EM resistance were not greater than three fold.
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These low resistance levels were achievable only after multi-
ple rounds of selection in increasing concentrations of drug
and required a period of over a year to acquire. Although
single-round selections typically yield 2-3 fold drug resis-
tance in microtubule mutants, multiple rounds of selection
have resulted in much higher levels of resistance to the
selecting drug (Schibler & Cabral, 1985). In addition to the
low level of achievable EM resistance, a low mutation fre-
quency (< 10-6) was observed for the clones. These results,
as well as the observation that the EMR lines are stable to
resistance when removed from drug, suggest that some type
of genetic alteration rather than an induction phenomenon
may be contributing to drug resistance.
Because of the important role that MDR plays in deter-
mining preclinical response to certain anti-cancer drugs, we
examined whether or not the EMR clones demonstrated
resistance mechanisms characteristic of this phenotype. Re-
sults from a series of collateral resistance and biological
characterisation assays indicate that EM resistance is distinct
from the MDR phenotype. EMR clones exhibit no cross
resistance to other anti-mitotic/MDR agents including adria-
mycin, cytochalasin B, taxol and vinblastine. In addition, two
cell lines known to be part of the MDR phenotype, SKVLB
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Figure 5 Differential interference contrast microscopy pictures
of mitotic figures in EMR cells treated with 16 tM EM at
anaphase onset. a metaphase, b anaphase A, c anaphase B, d
telophase. The time required for cells to progress through
anaphase, telophase, and cytokinesis was not effected by EM
treatment. Bar = 10 ElM.
Figure 6 Time courses of uptake a and release b of 3H-EM by
wild type (0) and EMR (A, 0, *) cells. EM uptake is express-
ed as nmoles 10-6 cells. All cell lines reached maximum drug
uptake by one hour. EMR 4 (A) and 9 (0) incorporate less total
drug and have smaller cellular volumes than wild type. Drug
efflux profile for wild type cells b is presented as % maximum
drug incorporated at time zero. The efflux rate constants, deter-
mined by nonlinear regression analysis, are much greater for
EMR clones than wild type cells. Each data point represents the
mean of two experiments done in triplicate.
and ARN, do not exhibit increased resistance to EM.
Finally, EMR clones do not express increased mRNA or
protein levels of P-glycoprotein. These results led us to con-
clude that the EMR clones do not display the MDR pheno-
type. Overexpression of GST isozymes have been implicated
in acquired drug resistance (Wang & Tew, 1985) including
the MDR phenotype (Batist et al., 1986; Schisselbauer et al.,
1989). Thiol-containing molecules, such as glutathione, have
been shown to have a critical role in maintaining microtubule
structure and organisation of the mitotic spindle during cell
division (Kimura, 1973; Onefelt, 1983; Tew et al., 1985). EM
may be a substrate for GST and has been shown previously
to influence GSH levels and GST activity in wild type
DU 145 cells (Tew et al., 1986). However, we found that the
selection pressures producing a stable EM-resistant pheno-
type do not result in a significantly altered expression of GST
or modified intracellular GSH.
Vinblastine and taxol are known to elicit anti-microtubule
effects through their direct interaction with tubulin (Bryan,
1971; Schiff et al., 1979). The fact that the EMR clones
remain sensitive to both microtubule stabilising as well as
destabilising agents suggests that these cells do not express a
tubulin alteration (Schiff & Horwitz, 1980). Of interest is the
increased sensitivity to cytochalasin B expressed by the EMR
lines. In contrast to tubulin targeting agents, cytochalasin B
binds to actin and affects microfilament assembly (MacLean-
Fletcher & Pollard, 1980). Thus, an increased sensitivity of
EMR lines to cytochalasin B suggests a possible alteration in
microtubule/microfilament interactions not seen in wild type
cells. It has been shown that MAPs are involved in micro-
tubule/microfilament interactions; therefore, an alteration in
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a MAP may be responsible for the observed increased sensi-
tivity to cytochalasin B of EMR lines (Griffith & Pollard,
1978; Selden & Pollard, 1983).
Frequently, the cytotoxic consequences of anti-microtubule
drugs will be manifested through effects on the mitotic spin-
dle, since the microtubule component making up this struc-
ture demonstrates increased sensitivity to the drugs. EM has
also been demonstrated to affect cells during mitosis, causing
a mitotic arrest in both DU 145 and PC-3 prostate cancer
lines (Hartley-Asp, 1984). We have recently shown that EM
inhibits metaphase to anaphase transition, reduced spindle
pole elongation and delays onset of cytokinesis in wild type
cells (Sheridan et al., 1991). Utilising FACs in conjunction
with light microscopy, we compared the effect of EM on the
cell cycle of the wild type and resistant cells. Results from
FACs analysis revealed that an increased percentage of wild
type cells were blocked in the G2/M phase of the cell cycle in
response to increasing EM concentrations. These findings are
consistent with the reported stathmokinetic effects of the
drug (Tew & Hartley-Asp, 1984). In contrast, EM concentra-
tions up to 20 JAM did not result in an increased percentage of
EMR cells blocked in G2/M. Moreover, population doubling
times of the EMR lines were not significantly different from
wild type; although, the trend was somewhat shorter. In
addition, wild type cells had nearly double the DNA content
of the EMR clones, suggesting that selection favoured cells
with reduced DNA content. Microscopic observations of
mitotic EMR cells (Figure 5) revealed that they have a
smaller mitotic spindle apparatus. We hypothesise that the
reduced chromosome number (unpublished observations) of
the EMR clones is related to the smaller mitotic spindle, and
perhaps reflects a propensity for cells with altered spindle
components to survive the EM challenge. Of interest, MAPs
have been shown to stimulate DNA synthesis in vitro, sugges-
ting a role for these proteins in the regulation of DNA
replication (Shioda et al., 1989). Cellular DNA is not a target
for EM (Tew et al., 1983; Hartley-Asp, 1984); however,
recent studies showed nuclear uptake of the drug (Hartley-
Asp & Kruse, 1986). The authors report that EM binds to
the nuclear protein matrix, possibly through interactions with
a MAP-like protein. Thus, one may speculate that EM bind-
ing to nuclear MAPs indirectly interferes with DNA syn-
thesis, and resistant cells have adapted through a decreased
DNA content with concomitantly fewer chromosomes.
Alterations in drug transport mechanisms are correlated
with the development of resistance. The possibility that EMR
clones were either drug uptake or efflux mutants was exam-
ined using 3H-EM. Estramustine's ability to freely cross cel-
lular membranes indicates little role for altered mechanisms
of uptake, such as energy-dependent or carrier-mediated, in
the development of resistance. Our results confirm this. The
rapid incorporation of EM into wild type and EMR cells is
consistent with reported patterns of EM uptake in human
prostate cancer (1013L) and HeLa S3 cell lines (Kruse &
Hartley-Asp, 1989). Similar to our findings, the authors dem-
onstrated 50-60% EM uptake within 5 min and maximum
uptake by 1 h. The maximum EM content of two of the
resistant clones was only half that of the wild type line.
However, the modal cellular volumes of these clones was also
only 50% of the wild type. Thus, we conclude that altered
drug uptake is not responsible for the development of EM
resistance. Results from drug efflux studies indicate that the
EMR clones do have altered patterns of EM extrusion. All
three resistant clones had much greater initial efflux rate
constants than wild type cells. The exact mechanisms respon-
sible for the enhanced EM efflux from resistant cells remains
to be elucidated; however, we have definitively demonstrated
that P-glycoprotein is not expressed in the cells. We cannot
conclude at this time that the enhanced EM efflux from the
EMR cells has a role in their development of resistance. The
wild type cells may have increased levels of EM binding
protein or possibly sequester the drug in organelles such as
vesicles. Either of these events would result in increased drug
accumulation and hence decreased drug efflux. These hypo-
theses are currently being investigated.
The lack of cross resistance demonstrated by the EMR
lines has significant therapeutic implications and can be the
basis for use of EM in combination with other chemo-
therapeutic agents. Biochemical analysis and discovery of the
unique mechanism of action of EM serves as the rationale
for its use in combination with anti-microtubule agents.
Using a tubulin-binding drug in addition to EM would
appear to be a rational approach to enhance cytotoxicity
through anti-microtubule activity. This concept is supported
by in vitro studies which demonstrated that EM enhanced the
effect of vinblastine on microtubule disassembly in malignant
mouse and DU 145 cell lines (Mareel et al., 1988). This
pre-clinical rationale, together with the non-overlapping host
toxicities of EM and vinblastine create an encouraging basis
for evaluation of this combination in human diseases. An
early Phase II trial escalating vinblastine to dose-limiting
toxicities produced equivocal results (van Belle et al., 1988).
We have initiated a Phase II study where EM doses are
escalated, while maintaining vinblastine at non-toxic levels.
From the pre-clinical data, there is no reason to assume that
resistance to one agent will be accompanied by collateral
resistance to the other.
The authors would like to thank Donna Bunch for the preparation
of this manuscript.
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